Pharmaceuticals

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

Data shows Beren Therapeutics' drug slows progression and boosts survival for infantile-onset NPC, a rare disorder with no approved US treatments.

A landmark review decodes how ketogenic diets treat epilepsy, highlighting a major research gap and sparking a quest for drugs that mimic the diet's effects.

Medical Knowledge Group appoints Waymo's David Margines, signaling a major shift in how high-stakes AI will reshape pharmaceutical marketing and strategy.

Global CRO Emerald Clinical Trials has won a major award for its patient-first strategies in the fast-growing, complex Asia-Pacific clinical trial market.

With new clinical data and a clear path to Phase 2 trials, Gain Therapeutics' GT-02287 offers hope for a disease-modifying therapy for Parkinson's.

Ratio Therapeutics appoints Dr. Colin Hayward as CMO, a strategic move to advance its sarcoma trial and challenge leaders in the booming radiopharmaceutical market.

A new clinical trial begins for APAC, a first-in-class drug aiming to prevent amputation and death from severe peripheral artery disease.

A novel compound, IRX4204, shows promise in preventing triple-negative breast cancer in lab studies, offering new hope for a safe, effective preventative.

Psyence BioMed is building a pharmaceutical powerhouse by controlling its supply chain, a strategic move that could redefine the future of psychedelic medicine.

The deal with Ahngook Pharm for its GMRx2 single-pill therapy marks a key step in a global strategy validated by recent US FDA approval.

The tech firm is launching a new transparent, scenario-based AI to de-risk the multi-billion dollar drug development pipeline. But can it succeed?

The biopharma firm's new dividend policy reflects strong 2025 results and a dual strategy of rewarding shareholders while funding M&A and expansion.

With a massive new investment, Vima Therapeutics advances a first-in-class oral drug into Phase 2, offering new hope beyond injections and surgery.

A new study validating patient-reported outcomes in HAE is set to standardize clinical trials, strengthening the case for new oral therapies like deucrictibant.

A new study reveals prior authorization policies cause critical delays for heart failure drugs, disproportionately harming vulnerable groups and raising safety concerns.

A landmark CHF 83.5M deal brings corticorelin, a promising steroid-sparing therapy for brain cancer patients, to Japan, offering a new frontier in care.

As automation demand soars, ATS Corp. will meet investors to outline its strategy for navigating market shifts and capitalizing on life sciences growth.

Following a major investment, Trialbee appoints a seasoned leader to its board, signaling a push for dominance in AI-driven clinical trial recruitment.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.